Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite

Area of Science:

• Toxicology
• Pharmacology
• Tropical Medicine

Background:

• Snakebite envenoming is a global health issue, prioritized by the WHO as a Neglected Tropical Disease (NTD).
• Significant mortality (~75%) occurs pre-hospital, highlighting the critical need for timely interventions.
• The delay in accessing antivenom treatment presents a major therapeutic challenge.

Purpose of the Study:

• To discuss the characteristics, potential applications, and development of small molecule therapeutics (SMTs) for snakebite envenomation.
• To explore SMTs, particularly secretory phospholipase A2 (sPLA2) inhibitors, as potential prereferral treatments.
• To briefly examine other drug targets on venom molecules for SMT development.

Main Methods:

• Review and discussion of existing literature on SMTs for snakebite.
• Focus on the mechanism of action of sPLA2 inhibitors.
• Exploration of drug development pathways for SMTs.

Main Results:

• SMTs offer a promising avenue for prereferral management of snakebite.
• sPLA2 inhibitors are a key class of SMTs with potential efficacy.
• Further research and development are needed to optimize SMTs for clinical use.

Conclusions:

• SMTs, especially sPLA2 inhibitors, could significantly improve outcomes for snakebite victims by enabling early treatment.
• Addressing the pre-hospital treatment gap with SMTs is crucial for reducing snakebite mortality.
• Continued investigation into SMTs and other venom targets is warranted.